Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Senti Biosciences (SNTI) EBT (2021 - 2025)

Senti Biosciences (SNTI) has 5 years of EBT data on record, last reported at -$16.8 million in Q3 2025.

  • For Q3 2025, EBT fell 11.4% year-over-year to -$16.8 million; the TTM value through Sep 2025 reached -$65.2 million, down 4.52%, while the annual FY2024 figure was -$60.1 million, 33.13% up from the prior year.
  • EBT reached -$16.8 million in Q3 2025 per SNTI's latest filing, down from -$16.5 million in the prior quarter.
  • Across five years, EBT topped out at -$1178.0 in Q1 2021 and bottomed at -$43.3 million in Q3 2023.
  • Average EBT over 5 years is -$14.4 million, with a median of -$15.9 million recorded in 2024.
  • Peak YoY movement for EBT: plummeted 997692.87% in 2022, then surged 65.2% in 2024.
  • A 5-year view of EBT shows it stood at -$3.9 million in 2021, then crashed by 306.16% to -$15.7 million in 2022, then decreased by 16.63% to -$18.3 million in 2023, then grew by 12.78% to -$15.9 million in 2024, then fell by 5.3% to -$16.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for EBT were -$16.8 million in Q3 2025, -$16.5 million in Q2 2025, and -$16.0 million in Q1 2025.